

IS GROWTH HORMONE DEFICIENCY A CONTRIBUTOR TO SHORT STATURE IN CUTIS LAXA SYNDROME?

Alice Ioana Albu^{1,2}, Delia Irina Nicolaescu¹, Denisa Dincă¹

1. Elias Hospital, Endocrinology and Diabetes Department, Bucharest, Romania

2. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania



Autosomal dominant cutis laxa type 3 (ADCL3) is a genetic connective tissue disorder characterized by poor pre- and postnatal growth and, rarely, by systemic impairment. The aetiology of short stature is incompletely known, some of these patients reaching normal final height. Less than 50 cases were reported in the literature.

We report the case of a male patient 3.2 years old who presented for endocrinological evaluation of short stature.

Medical history: congenital hypothyroidism treated with levo-thyroxin, congenital cataract, pseudoaphakia, hiatal hernia, micturition disorder. The patient was born small for gestation age (SGA) with birth weight of 2080 g and birth length 41 cm at 38 weeks of gestation

Clinical exam: severe short stature (-4,08 standard deviations, SD), facial dysmorphic features, lax, thin skin with vascular markings,, body weight at the upper normal range (BMI at the 80 percentile) and decreased growth velocity (-1,76 SD in the last year).

Paraclinical exams:

- IGF1=111 ng/ml (normal range 49-283),
- peak growth hormone (GH) during two stimulation tests of 8,07 ng/ml and 2,98 ng/ml,
- Adrenal and thyroid tests normal
- bone age: 3 years
- pituitary MRI: pituitary hypoplasia


Diagnosis: short stature due to SGA and growth hormone deficiency

Treatment: somatropin 0,035 mcg/kg body weight/day

The patient was send for genetic examination and the genetic tests showed ADCL3.

Evolution under treatment with somatropin

- **at 6 months:** the patient gained 5 cm in height, the height SDS was -3,44 DS;
- **at 12 months:** the patient gained 5,3 cm in height, SDS for height -3,1, IGF 1 = 220 ng/ml (normal range: 49 -283 ng/ml),



This is the first case report of ADCL3 associated with GH deficiency treated with somatropin. Evolution under treatment will be closely followed in interdisciplinary collaboration to optimize the results.

References:

1. Wolthuis, D. F. G. J., van Asbeck, E., Mohamed, M., Gardeitchik, T., Lim-Melia, E. R., Wevers, R. A., Morava, E. Cutis laxa, fat pads and retinopathy due to ALDH18A1 mutation and review of the literature. *Europ. J. Paediat. Neurol.* 18: 511-515, 2014.
2. Mohamed M, Kouwenberg D, Gardeitchik T, et al. Metabolic cutis laxa syndromes. *J Inherit Metab Dis.* 2011;34:907-916. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137780/>

